Nanoparticle-Based Radioconjugates for Targeted Imaging and Therapy of Prostate Cancer.

ABSTRACT: Prostate cancer is the second most frequent malignancy in men worldwide and the fifth leading cause of death by cancer. Although most patients initially benefit from therapy, many of them will progress to metastatic castration-resistant prostate cancer, which still remains incurable. The significant mortality and morbidity rate associated with the progression of the disease results mainly from a lack of specific and sensitive prostate cancer screening systems, identification of the disease at mature stages, and failure of anticancer therapy. To overcome the limitations of conventional imaging and therapeutic strategies for prostate cancer, various types of nanoparticles have been designed and synthesized to selectively target prostate cancer cells without causing toxic side effects to heal

SUBMITTER: Lankoff A 

PROVIDER: S-EPMC10223532 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature